drugset
drugset / Trial / NCT05108623

A Study Investigating agenT-797 in Participants With Relapsed/Refractory Solid Tumors

NCT05108623 ↗

Phase 1 Completed 34 enrolled MiNK Therapeutics
Non-randomizedSequentialOpen-labelTreatment

Summary

This is a Phase 1, open-label study to explore the safety, tolerability, and preliminary clinical activity of agenT-797, an unmodified, allogeneic iNKT cell therapy, in participants with relapsed/refractory (r/r) solid tumors, as well as define the recommended phase II dose in solid tumors. This Phase 1 study will also explore the safety, tolerability, and preliminary clinical activity of agenT-797 in combination with approved immune checkpoint inhibitors (ICIs), including pembrolizumab and nivolumab, in participants with r/r solid tumors.

Timeline

Start
2022-01-28
Primary completion
2024-01-02
Completion
2024-01-02

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject agenT-797 Cell therapy — Intravenous
Background Nivolumab Monoclonal antibody — —
Background Pembrolizumab Monoclonal antibody — —

Indications

No indication recorded.